The place of rosuvastatin in lipid-lowering therapy in patients with different levels of cardiovascular risk: clinical and pharmacoeconomic efficiency


Cite item

Full Text

Abstract

Rosuvastatin is the latest generation inhibitor of HMG-CoA reductase. Its high efficacy and safety along with small number of interaction with the cytochrome P450 system represent obvious advantages in the therapy of dyslipidemia, one of the main factors in the development of cardiovascular diseases. The purpose of this study was to evaluate the cost-effectiveness of the generic rosuvastatin (Rozart) in patients characterized by various levels of cardiovascular risk. The study was conducted from the perspective of the health care system using the Markov modeling method (10 years). The results of the study demonstrated that the cost-effectiveness of rosuvastatin administered as part of the primary prevention of CAD increases with an increase in the level of cardiovascular risk, while the secondary prevention of CAD is even more cost-effective vs primary prevention.

About the authors

I. V Sergienko

National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., вед. науч. сотр. отд. проблем атеросклероза, дир. Национального общества по изучению атеросклероза 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15a

A. V Rudakova

Saint Petersburg State Chemical Pharmaceutical Academy of the Ministry of Health of the Russian Federation

д-р фарм. наук, проф. каф. управления и экономики фармации 197376, Russian Federation, Saint Petersburg, ul. Professora Popova, d. 14, lit. A

E. V Karpova

Teva Pharmaceutical Industries Ltd

Email: Ekaterina.Karpova03@teva.ru
канд. мед. наук 115093, Russian Federation, Moscow, ul. Valovaia, d. 35

References

  1. Chazova I.E. et al. Prevalence of Cardiovascular Risk Factors in Russian Population of Patients With Arterial Hypertension. Kardiologiia 2014; 10: 4-12.
  2. Yusuf S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
  3. Cooney M.T, Dudina A.L, Graham I.M. Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk. J Am Coll Cardiol 2009; 54: 1209-27.
  4. Risk Functions. Framingham Heart Study. Available at: https://www.framinghamheartstudy.org/risk-functions/
  5. D’Agostino R.B. et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. Circulation 2008; 117: 743-53.
  6. SCORE Risk Charts. Available at: https://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/SCORE-Risk-Charts.
  7. Goff D.C. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S49-73.
  8. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002; 105: 310-5.
  9. WHO | Cardiovascular risk prediction charts. WHO. 2014.
  10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Dudina M.T, D’Agostino R.B, Graham I.M. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
  11. Conroy R.M. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
  12. Сергиенко И.В., Ежов М.В., Кухарчук В.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Атеросклероз и дислипидемии. 2017; 3: 5-23.
  13. Рабочая группа Европейского общества кардиологов (ЕОК) и Европейского общества атеросклероза (ЕОА) по лечению дислипидемий. Рекомендации Европейского общества кардиологов и Европейского общества атеросклероза по лечению дислипидемий. Рациональная фармакотерапия в кардиологии (Прил.). 2012; 1-3.
  14. Pereira T. In Dyslipidemia - From Prevention to Treatment (InTech, 2012). doi: 10.5772/27378.
  15. Catapano A.L. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37: 2999-3058.
  16. Cholesterol Treatment Trialists’ (CTT) Collaboration, C. T. T. (CTT) et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
  17. Rosenson R.S. Statins: Actions, side effects, and administration. Available at: https://www.uptodate.com/ contents/statins-actions- side-effects-and-administration (2017).
  18. Crouse J.R. et al. Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis. JAMA 2007; 297: 1344.
  19. Hu M, Tomlinson B. Current Perspectives on rosuvastatin. Integr. Blood Press Control 2013; 6: 15-25.
  20. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev. Cardiovasc Ther 2007; 5: 177-93.
  21. Karlson B.W, Barter P.J, Palmer M.K. et al. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: Results from VOYAGER. Nutr Metab Cardiovasc Dis 2012; 22: 697-703.
  22. Rosenson R.S, Otvos J.D, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care 2009; 32: 1087-91.
  23. Barter P.J, Brandrup-Wognsen G, Palmer M.K, Nicholls S.J. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 2010; 51: 1546-53.
  24. Jones P.H. et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60.
  25. Bakker-Arkema R.G. et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-33.
  26. Davidson M. et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79: 1475-81.
  27. Mulder A.B. et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70: 546-51.
  28. Chasman D.I. et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291: 2821-7.
  29. Bakhai A, Rigney U, Hollis S, Emmas C. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf 2012; 21: 485-93.
  30. White C.M. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963-70.
  31. Olsson A.G, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002; 20: 303-28.
  32. Rosenson S.R, Baker S.K. Statin myopathy (2016). Available at: https://www.uptodate.com/ contents/statin-myopathy
  33. García-Rodríguez L.A, Massó-González E.L, Wallander M-A, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008; 17: 943-52.
  34. Ridker P.M .et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
  35. Sattar N. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42.
  36. Shalnova S.A. et al. Awareness and treatment specifics of statin therapy in persons with various cardiovasular risk: the study ESSE-RF. Cardiovasc Ther Prev 2016; 15: 29-37.
  37. Rawlings R. et al. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol 2009; 103: 437-41.
  38. Durrington P.N, Tuomilehto J, Hamann A. et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004; 64: 137-51.
  39. Rosenson R.S. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003; 1: 495-505.
  40. Teramoto T, Watkins C. Review of efficacy of rosuvastatin 5 mg. Int J Clin Pract 2005; 59: 92-101.
  41. Ullah F, Afridi A.K, Rahim F. et al. Efficacy of 5 mg and 10 mg rosuvastatin in type-2 diabetes mellitus with hypercholesteroalemia. J Ayub Med Coll Abbottabad 2015; 27: 564-8.
  42. Meek C. et al. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin 2012; 28: 371-8.
  43. Olsson A.G. et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002; 144: 1044-51.
  44. Clearfield M.B. et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia - Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 2006; 7: 35.
  45. Berne C, Siewert-Delle A, URANUS study investigators, the U. study. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005; 4: 7.
  46. Cevc M. Comparison of efficacy and safety of rosuvastatin 15 mg vs. 10 mg: subanalysis of the ROSU-PATH trial (2016). http://congress365.escardio.org/Presentation/ 140210#.Wf0HX1u0Opp
  47. Schuster H. et al. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart J 2004; 147: 705-12.
  48. Bando Y. et al. Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus. Diabet Res Clin Pract 2016; 111: 66-73.
  49. Stein E.A. et al. Long-Term Efficacy and Safety of Rosuvastatin 40 mg in Patients With Severe Hypercholesterolemia. Am J Cardiol 2007; 100: 1387-96.
  50. Leiter L.A. et al. Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 2007; 194: e154-e164.
  51. Lipid-modifying drugs. 2015. Available at: https://www.nice.org. uk/guidance/ktt3/resources/ lipidmodifying-drugs-pdf-1632168482245
  52. Hirsch M, O’Donnell J.C, Jones P. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Eur J Cardiovasc Prev Rehabil 2005; 12: 18-28.
  53. Gandhi S. et al. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. Clin Outcomes Res 2012; 4: 1.
  54. Hlatky M. The Cost-Effectiveness of Rosuvastatin Therapy. J Am Coll Cardiol 2011; 57: 792-3.
  55. Costa-Scharplatz M, Ramanathan K, Frial T .et al. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective. Clin Ther 2008; 30: 1345-57.
  56. Гофман Е.А. и др. Первые результаты исследования «Прогноз ИБС». Клиницист. 2012; 1: 56-62.
  57. Montalescot G et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.
  58. Гинзбург М.Л. Изучение отдаленных результатов лечения больных, перенесших острый инфаркт миокарда, и оценка факторов риска, определяющих прогноз их жизни. Автореф. дис. … д-ра мед. наук. М.: Государственный научно-исследовательский центр профилактической медицины Минздрава России, 2013.
  59. Ward S et al. A systematic review and economic evaluation of statins for the prevention of coronary events. NIHR Heal Technol Assess Program Exec Summ 2007; 11: 1-160.
  60. Джаиани Н.А., Ильина Е.В., Терещенко С.Н. Современные аспекты применения статинов при остром инфаркте миокарда. Сердце. 2007; 6: 85.
  61. McConnachie A. et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur Heart J 2013; 35: 290-8.
  62. Neyt M, Laet C, Brabandt H. et al. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. Acta Cardiol 2009; 64: 1-10.
  63. Peura P, Martikainen J, Soini E et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008; 24: 1823-32.
  64. Ito M.K. et al. Statins for Cardiovascular Prevention According to Different Strategies. Am J Cardiovasc drugs 2011; 11: 33-44.
  65. Маль Г.С., Желудков И.С., Мешков А.И. К вопросу о фармакоэкономике статинов при лечении ИБС. Совр. наукоемкие технологии. 2004; 6.
  66. Рудакова А.В. Статины в терапии ишемической болезни сердца: фармакоэкономические аспекты. Сердце. 2008; 7: 227-33.
  67. Brugts J.J, Yetgin T, Hoeks S.E. et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376. doi: 10.1136/bmj.b2376

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies